Could CureVac Be a Millionaire-Maker Stock?
Coronavirus vaccine stocks likely have turned many investors into millionaires over the past year. Players like Novavax and Vaxart climbed 2,700% and 1,500%, respectively, as two of last year's biggest gainers. Investors who were early believers in those companies saw their investments soar. The movement isn't over. Vaccine stocks still have room to grow. Experts say the coronavirus is here to stay -- and that means strong revenue prospects ahead.
So, let's look at another vaccine stock. This particular one has given investors high hopes -- until a recent trial data report. I'm talking about CureVac (NASDAQ: CVAC). The biotech company is studying its mRNA vaccine in a pivotal phase 2b/3 trial. Do shares of CureVac have the potential to make you a millionaire? Or has the recent news closed the door on that possibility?
Image source: Getty Images.
Source Fool.com
